Chinese biopharma firm EpimAb bags $120m Series C co-led by CMBI, Mirae Asset

Chinese biopharma firm EpimAb bags $120m Series C co-led by CMBI, Mirae Asset

Photo: Pixabay

Shanghai-based clinical-stage biotech company EpimAb Biotherapeutics announced on Tuesday that it has raised $120 million in a Series C round of financing.